D. Wiederschain

发表

DNA Damage-induced MDMX Degradation Is Mediated by MDM2*

Jeremy R Stuart, H. Kawai, D. Wiederschain, 2003, Journal of Biological Chemistry.

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

A. Iafrate, K. Flaherty, H. Wakimoto, 2015, Cancer cell.

Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition

D. Wiederschain, C. Winter, J. Pollard, 2017, PloS one.

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.

D. Wiederschain, H. van de Velde, M. Chiron, 2021, Blood.

Multiple Mixed Lineage Leukemia (MLL) Fusion Proteins Suppress p53-mediated Response to DNA Damage*

A. Shilatifard, H. Kawai, D. Wiederschain, 2005, Journal of Biological Chemistry.

Anti–miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation

R. Baffa, A. Pavlícek, Sung‐Min Ahn, 2015, Molecular Cancer Research.

A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

G. Nabel, D. Wiederschain, Huawei Qiu, 2022, Nature.

Dual Role of p300 in the Regulation of p53 Stability*

H. Kawai, D. Wiederschain, Zhi-Min Yuan, 2001, The Journal of Biological Chemistry.

Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy

K. Grandien, D. Wiederschain, Felix A Gnerlich, 2019, Molecular Cancer Therapeutics.

Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.

H. Kawai, D. Wiederschain, Z. Yuan, 2001, Cancer research.

Molecular Basis of p53 Functional Inactivation by the Leukemic Protein MLL-ELL

A. Shilatifard, H. Kawai, D. Wiederschain, 2003, Molecular and Cellular Biology.

The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro.

J. Mulliken, D. Wiederschain, M. Moses, 1999, Journal of cell science.

Mutual Dependence of MDM 2 and MDMX in Their Functional Inactivation of p 53 *

H. Kawai, D. Wiederschain, H. Kitao, 2002 .

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

D. Wiederschain, S. Guérif, V. Blanc, 2021, Oncoimmunology.

Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53*

A. Jochemsen, H. Kawai, D. Wiederschain, 2002, The Journal of Biological Chemistry.

Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.

D. Wiederschain, J. Arbiser, D. Frank, 2000, The American journal of pathology.

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

D. Wiederschain, F. Nestle, Sharad K Sharma, 2022, Journal for ImmunoTherapy of Cancer.

Increased incidence of matrix metalloproteinases in urine of cancer patients.

M A Moses, D. Zurakowski, D. Wiederschain, 1998, Cancer research.

Troponin I is present in human cartilage and inhibits angiogenesis.

R. Langer, William Arbuthnot Sir Lane, A. Sytkowski, 1999, Proceedings of the National Academy of Sciences of the United States of America.

PTEN-deficient cancers depend on PIK3CB

Alice T. Loo, D. Wiederschain, F. Stegmeier, 2008, Proceedings of the National Academy of Sciences.

Single-vector inducible lentiviral RNAi system for oncology target validation

J. D. Benson, W. Sellers, G. Caponigro, 2009, Cell cycle.

Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule

Dietmar Hoffmann, Jean-Pierre Marquette, Magali Mathieu, 2014, The Journal of Biological Chemistry.

Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation

D. Wiederschain, C. Winter, L. Schweizer, 2017, Oncotarget.

Dysregulated proteolytic balance as the basis of excess extracellular matrix in fibrotic disease.

D. Wiederschain, M. Moses, M. Freeman, 1997, The American journal of physiology.

Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo

John A. Tallarico, M. Schirle, Christopher J. Wilson, 2014, Nature Cell Biology.

Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models

G. Nabel, D. Wiederschain, U. Şahin, 2021, Science Translational Medicine.

Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development

D. Wiederschain, C. Lengauer, S. Wee, 2008, Current opinion in oncology.

Extreme Vulnerability of ID H 1 Mutant Cancers to NAD + Depletion Graphical Abstract Highlights

A. Iafrate, K. Flaherty, H. Wakimoto, 2022 .

The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells.

Michael P. Morrissey, W. Sellers, J. Monahan, 2010, Cancer research.

Contribution of Polycomb Homologues Bmi-1 and Mel-18 to Medulloblastoma Pathogenesis

J. D. Benson, Michael P. Morrissey, Michael D. Jones, 2007, Molecular and Cellular Biology.

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade

A. Protopopov, D. Wiederschain, C. Winter, 2020, Oncoimmunology.

An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy

Joon Sang Lee, D. Wiederschain, J. Pollard, 2021, Oncoimmunology.

Critical Contribution of the MDM2 Acidic Domain to p53 Ubiquitination

H. Kawai, D. Wiederschain, Zhi-Min Yuan, 2003, Molecular and Cellular Biology.

Evidence for a Distinct Inhibitory Factor in the Regulation of p53 Functional Activity*

D. Wiederschain, Zhi-Min Yuan, Jijie Gu, 2001, The Journal of Biological Chemistry.

PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene.

S. Gross, Q. Gao, D. Wiederschain, 2014, Blood.

suppression of STAT 5 activation and degradation of MYC oncogene PIM inhibitors target CD 25-positive AML cells through concomitant

S. Gross, Q. Gao, D. Wiederschain, 2014 .

Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms

D. Wiederschain, C. García-echeverría, C. Lengauer, 2014, Oncotarget.

The generation of endostatin is mediated by elastase.

J. Folkman, D. Wiederschain, J. Arbiser, 1999, Cancer research.

Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance*

J. Folkman, W. Stetler-Stevenson, D. Wiederschain, 1999, The Journal of Biological Chemistry.

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

D. Wiederschain, M. Chiron, Helen Lee, 2019, Cells.

Evaluation of Cancer Dependence and Druggability of PRP4 Kinase Using Cellular, Biochemical, and Structural Approaches

Q. Gao, D. Wiederschain, C. García-echeverría, 2013, The Journal of Biological Chemistry.

Identification of p53 Sequence Elements That Are Required for MDM2-Mediated Nuclear Export

D. Wiederschain, Zhi-Min Yuan, J. Gu, 2001, Molecular and Cellular Biology.

Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP)

Mihee M. Kim, D. Wiederschain, D. Kennedy, 2007, Oncogene.

Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model.

M A Moses, J. Harper, D. Wiederschain, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Metal Binding Network by an Allosteric Dehydrogenase 1 ( IDH 1 ) via Disruption of Selective Inhibition of Mutant Isocitrate Enzymology

S. Gross, Q. Gao, D. Wiederschain, 2014 .

Dynamics of extracellular matrix production and turnover in tissue engineered cardiovascular structures

Susan M. Kilroy, J. Mayer, J. Vacanti, 2001, Journal of cellular biochemistry.

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody

Changyun Hu, D. Wiederschain, M. Gostissa, 2022, Oncoimmunology.

Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents

Thomas Bertrand, Bailin Zhang, Lionel Bert, 2015, Scientific Reports.

An iron-dependent metabolic vulnerability underlies VPS34-dependence in RKO cancer cells

D. Wiederschain, M. Beibel, S. Menon, 2020, PloS one.

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

D. Wiederschain, M. Chiron, Y. Tai, 2020, Frontiers in Immunology.

Abstract 1825: SAR443216, a novel trispecific T cell engager with potent T cell-dependent cytotoxicity for HER2-low tumors

G. Nabel, V. Pelekanou, D. Wiederschain, 2021, Immunology.

RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity.

Mihee M. Kim, H. Kawai, D. Wiederschain, 2007, Cancer research.

Tumor-Specific Urinary Matrix Metalloproteinase Fingerprinting: Identification of High Molecular Weight Urinary Matrix Metalloproteinase Species

Susan M. Kilroy, D. Zurakowski, D. Wiederschain, 2008, Clinical Cancer Research.

Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cells

Madelyn Light, Q. Gao, D. Wiederschain, 2014, Nucleic acids research.

Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy

Tun Tun Lin, P. Mankoo, D. Wiederschain, 2018, Clinical Research (Excluding Clinical Trials).

Contribution of Polycomb Homologues Bmi-1 and Mel-18 to Medulloblastoma Pathogenesis

J. D. Benson, Michael P. Morrissey, Michael D. Jones, 2007, Molecular and Cellular Biology.

Matrix metalloproteinases and their inhibitors in aqueous humor.

D. Wiederschain, A. Adamis, Marsha A. Moses, 1996, Experimental eye research.

Abstract 1632: Antibody mediated crosslinking of CD38 triggers costimulatory signaling and promotes T cell effector function

Mun Kyung Hwang, D. Wiederschain, Shujia Dai, 2021, Immunology.